• 1. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 2. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090
• 3. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 4. Excimer–monomer switch: a reaction-based approach for selective detection of fluoride?
  Qiao Song,Angela Bamesberger,Lingyun Yang,Haley Houtwed,Haishi Cao Analyst, 2014,139, 3588-3592
• 5. Evidence that the availability of an allylic hydrogen governs the regioselectivity of the Wacker oxidation
  Matthew J. Gaunt,Jinquan Yu,Jonathan B. Spencer Chem. Commun., 2001, 1844-1845

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzopyrazoles Indazoles

Introduction to (6-Methoxy-1H-indazol-3-yl)-methanol (CAS No. 518990-05-1)

Compound (6-Methoxy-1H-indazol-3-yl)-methanol, identified by its CAS number 518990-05-1, is a significant molecule in the field of pharmaceutical chemistry and drug discovery. This compound belongs to the indazole class of heterocyclic aromatic compounds, which have garnered considerable attention due to their diverse biological activities and potential therapeutic applications.

The structural motif of (6-Methoxy-1H-indazol-3-yl)-methanol features a methoxy group at the 6-position of the indazole ring and a hydroxymethyl group at the 3-position. This specific arrangement of functional groups makes it a versatile scaffold for further chemical modifications and derivatization, enabling the development of novel bioactive molecules.

In recent years, indazole derivatives have been extensively studied for their pharmacological properties. The presence of the methoxy group enhances the lipophilicity and metabolic stability of the molecule, making it an attractive candidate for drug development. Additionally, the hydroxymethyl group provides a site for further functionalization, allowing chemists to tailor the compound's properties to specific biological targets.

One of the most compelling aspects of (6-Methoxy-1H-indazol-3-yl)-methanol is its potential in oncology research. Studies have demonstrated that indazole derivatives can modulate various signaling pathways involved in cancer cell proliferation and survival. For instance, some indazole-based compounds have shown inhibitory effects on kinases and other enzymes that are aberrantly expressed in tumor cells. This has led to interest in exploring (6-Methoxy-1H-indazol-3-yl)-methanol as a lead compound for developing targeted therapies against certain types of cancer.

Moreover, the compound has shown promise in preclinical studies as an anti-inflammatory agent. Inflammatory processes are implicated in a wide range of diseases, including autoimmune disorders and chronic inflammatory conditions. The ability of (6-Methoxy-1H-indazol-3-yl)-methanol to interact with specific inflammatory pathways suggests its potential as a therapeutic agent in these contexts.

Recent advances in computational chemistry and molecular modeling have further enhanced our understanding of the interactions between (6-Methoxy-1H-indazol-3-yl)-methanol and biological targets. These techniques allow researchers to predict binding affinities and optimize molecular structures, accelerating the drug discovery process. By leveraging these computational tools, scientists can design derivatives of (6-Methoxy-1H-indazol-3-yl)-methanol with improved pharmacokinetic profiles and enhanced biological activity.

The synthesis of (6-Methoxy-1H-indazol-3-yl)-methanol involves multi-step organic reactions that require careful optimization to ensure high yield and purity. Common synthetic routes include condensation reactions, nucleophilic substitutions, and functional group transformations. The availability of efficient synthetic methodologies is crucial for scaling up production and conducting extensive biological evaluations.

In conclusion, (6-Methoxy-1H-indazol-3-yl)-methanol (CAS No. 518990-05-1) represents a promising compound with significant potential in pharmaceutical research. Its unique structural features and biological activities make it an attractive scaffold for developing novel therapeutic agents. As research in this area continues to evolve, further insights into the pharmacological properties and mechanisms of action of this compound will undoubtedly emerge, paving the way for innovative treatments across multiple disease indications.

• 201286-99-9(6-Hydroxy-3-methylindazole)
• 64132-13-4(1H-indazol-3-ylmethanol)
• 518990-36-8(6-Methoxy-1H-indazole-3-carboxylic acid)
• 691900-59-1(6-Methoxy-1H-indazole-3-carbonitrile)
• 904086-08-4(3-Methyl-1H-indazol-5-ol)
• 154876-15-0(1H-Indazole,5,7-dimethoxy-3-methyl-)
• 29281-07-0(5,6-Dimethoxy-1H-indazole-3-carboxylic acid)
• 90417-53-1(5-Methoxy-1H-indazole-3-carboxylic Acid)
• 518987-37-6(6-Methoxy-1H-indazole-3-carbaldehyde)
• 865887-02-1(4-Methoxy-1H-indazole-3-carboxylic acid)